Citations

Clear

3138 citation(s) found for "Smith, AM".

Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma
Stephens, Deborah M. , Li, Hongli , Straus, David J. , Moskowitz, Craig H. , Bartlett, Nancy L. , Evens, Andrew M. , LaCasce, Ann S. , Knopp, Michael V. , Leonard, John P. , Smith, Sonali M. , Friedberg, Jonathan W. , Bartlett, Nancy L , Evens, Andrew M , Stephens, Deborah M , Schöder, Heiko , LeBlanc, Michael , Rimsza, Lisa M. , Barr, Paul M. , Hsi, Eric D. , Kahl, Brad S.

Mayo Clinic

Blood | July 23, 2019 | Volume: 134 | Issue: 15 | Pages: 1238-1246

10.1182/blood.2019000719 | PMID 31331918 Get It

AbstractThe investigators present results on the long-term value and limitations of early interim positron emission tomography (PET) scanning in advanced Hodgkin lymphoma.
NCCN Guidelines Insights: Survivorship, Version 2.2019
Sanft, Tara , Denlinger, Crystal S. , Demark‐Wahnefried, Wendy , Goldman, Mindy, Khakpour, Nazanin , Koura, Divya, Langbaum, Terry S., McDonough, Allison L. , Melisko, Michelle , Mooney, Kathi , Moslehi, Javid J. , O’Connor, Tracey L. , Overholser, Linda , Peterson, Lindsay L. , Pirl, William F. , Rodriguez, Maria Alma , Ruddy, Kathryn J. , Smith, Sophia K. , Syrjala, Karen L. , Urba, Susan G., Zee, Phyllis C. , McMillian, Nicole R., Freedman-Cass, Deborah A., Broderick, Gregory, Demark-Wahnefried, Wendy , Armenian, Saro H. , Baker, Kevin Scott , Broderick, Gregory A. , Friedman, Debra L. , Hudson, Melissa M. , Lally, Robin Mary , Moore, Halle C. F. , Paskett, Electra D. , Tevaarwerk, Amyé

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 18, 2019 | Volume: 17 | Issue: 7 | Pages: 784-794

10.6004/jnccn.2019.0034 | PMID 31319383 Get It

The NCCN Guidelines for Survivorship provide screening, evaluation, and treatment recommendations for consequences of cancer and cancer treatment to aid healthcare professionals who work with survivors of adult-onset cancer. Guidance is also provided to help promote physical activity, weight management, and proper immunizations in survivors and to facilitate care coordination to ensure that all needs are addressed. These NCCN Insights summarize some of the topics discussed by the NCCN Survivorship Panel during the 2019 update of the guidelines, including the survivorship population addressed, ways to improve care coordination, and pain management.
Loratadine for Paclitaxel-Induced Myalgias and Arthralgias
Smith, Caleb J. , Hendrickson, Andrea Wahner, Grudem, Megan E. , Klampe, Carolyn M., Deering, Erin, Jatoi, Aminah , Smith, Caleb , Grudem, Megan, Klampe, Carolyn

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | July 18, 2019 | Volume: 37 | Issue: 3 | Pages: 235-238

10.1177/1049909119864083 | PMID 31315424 Get It

Background: Seventy percentage of patients who receive paclitaxel have diffuse, refractory myalgias, and arthralgias. Based on anecdotal reports, this study explored whether loratadine, an antihistamine, palliates these symptoms. Methods: The medical records of postoperative ovarian and patients with endometrial cancer were studied, as these patients are routinely prescribed paclitaxel. Records were screened for patients who received paclitaxel and loratadine concurrently. Results: Forty patients are the focus of this report. Eight had paclitaxel-induced myalgias and arthralgias and then took loratadine; of these, 6 (75%; 95% confidence interval: 35%, 97%) manifested evidence of symptom improvement: “She did experience some migrating generalized body aches and pains…but this has resolved.” Of those already receiving loratadine but with no myalgias and arthralgias, only 11 of 32, or 34% (95% confidence interval: 19%, 53%), developed myalgias and arthralgias (in contrast to the previously reported symptom rate of 70%). No adverse events were clearly attributed to loratadine. Conclusion: These preliminary data support further study of loratadine for paclitaxel-induced myalgias and arthralgias.
Stanniocalcin-1 is a Modifier of Oxygen-Induced Retinopathy Severity
Hartnett, M. Elizabeth , Bretz, Colin A. , Hann, Cheryl R., Cui, Ricky Z. , Marmorstein, Alan D. , Sheikh‐Hamad, David , Fautsch, Michael P. , Roddy, Gavin W. , Roddy, Gavin W , Dalvin, Lauren A. , Hartnett, M. Elizabeth , Marmorstein, Alan D

Mayo Clinic

Current Eye Research | July 17, 2019 | Volume: 45 | Issue: 1 | Pages: 46-51

10.1080/02713683.2019.1645184 | PMID 31314602 Get It

Methods for the Watch the Spot Trial. A Pragmatic Trial of More- versus Less-Intensive Strategies for Active Surveillance of Small Pulmonary Nodules
Gould, Michael K. , Kelly, Karen , Altman, Danielle, Bie, Evan de, Dyer, Debra S. , Barbosa, Eduardo J. Mortani , Qi, Lihong , Vaszar, Laszlo T. , Yu, Sophronia , Miglioretti, Diana L. , Miglioretti, Diana L , Kelly, Karen , Smith‐Bindman, Rebecca , Barjaktarević, Igor , Creekmur, Beth , Mularski, Richard A.

Mayo Clinic

Annals of the American Thoracic Society | July 17, 2019 | Volume: 16 | Issue: 12 | Pages: 1567-1576

10.1513/annalsats.201903-268sd | PMID 31314549 Get It

Abstract Small pulmonary nodules are most often managed by surveillance imaging with computed tomography (CT) of the chest, but the optimal frequency and duration of surveillance are unknown. The Watch the Spot Trial is a multicenter, pragmatic, comparative-effectiveness trial with cluster randomization by hospital or health system that compares more- versus less-intensive strategies for active surveillance of small pulmonary nodules. The study plans to enroll approximately 35,200 patients with a small pulmonary nodule that is newly detected on chest CT imaging, either incidentally or by screening. Study protocols for more- and less-intensive surveillance were adapted from published guidelines. The primary outcome is the percentage of cancerous nodules that progress beyond American Joint Committee on Cancer seventh edition stage T1a. Secondary outcomes include patient-reported anxiety and emotional distress, nodule-related health care use, radiation exposure, and adherence with the assigned surveillance protocol. Distinctive aspects of the trial include: 1) the pragmatic integration of study procedures into existing clinical workflow; 2) the use of cluster randomization by hospital or health system; 3) the implementation and evaluation of a system-level intervention for protocol-based care; 4) the use of highly efficient, technology-enabled methods to identify and (passively) enroll participants; 5) reliance on data collected as part of routine clinical care, including data from electronic health records and state cancer registries; 6) linkage with state cancer registries for complete ascertainment of the primary study outcome; and 7) intensive engagement with a diverse group of patient and nonpatient stakeholders in the design and execution of the study.
Impaired central hemodynamics in chronic obstructive pulmonary disease during submaximal exercise
Smith, Joshua R. , Johnson, Bruce D. , Olson, Thomas P. , Smith, Joshua R

Mayo Clinic

Journal of Applied Physiology | July 11, 2019 | Volume: 127 | Issue: 3 | Pages: 691-697

10.1152/japplphysiol.00877.2018 | PMID 31295068 Get It

It is unknown whether central hemodynamics are impaired during exercise in chronic obstructive pulmonary disease (COPD) patients. We hypothesized that, at a similar absolute V̇o2 during exercise, COPD patients would have a lower stroke volume and cardiac output compared with healthy controls. Furthermore, we hypothesized that greater static hyperinflation [ratio of inspiratory capacity to total lung capacity (IC/TLC)] and expiratory intrathoracic pressure would be significantly related to the lower cardiac output and stroke volume responses in COPD patients. Clinically stable COPD ( n = 13; FEV1/FVC: 52 ± 13%) and controls ( n = 10) performed constant workload submaximal exercise at an absolute V̇o2 of ~1.3 L/min. During exercise, inspiratory capacity maneuvers were performed to determine operating lung volumes and cardiac output (via open-circuit acetylene rebreathe technique) and esophageal pressure were measured. At similar absolute V̇o2 during exercise ( P = 0.81), COPD had lower cardiac output than controls (COPD: 11.0 ± 1.6 vs. control: 12.2 ± 1.2 L/min, P = 0.03) due to a lower stroke volume (COPD: 107 ± 13 vs. control: 119 ± 19 mL, P = 0.04). The heart rate response during exercise was not different between groups ( P = 0.66). FEV1 (%predicted) and IC/TLC were positively related to stroke volume ( r = 0.68, P = 0.01 and r = 0.77, P < 0.01). Last, esophageal pressure-time integral during inspiration was positively related to cardiac output ( r = 0.56, P = 0.047). These data demonstrate that COPD patients have attenuated cardiac output and stroke volume responses during exercise compared with control. Furthermore, these data suggest that the COPD patients with the most severe hyperinflation and more negative inspiratory intrathoracic pressures have the most impaired central hemodynamic responses. NEW & NOTEWORTHY Chronic obstructive pulmonary disease leads to cardiac structural changes and pulmonary derangements that impact the integrative response to exercise. However, it is unknown whether these pathophysiological alterations influence the cardiac response during exercise. Herein, we demonstrate that COPD patients exhibit impaired central hemodynamics during exercise that are worsened with greater hyperinflation.
Comparison of sequence‐specific oligonucleotide probe vs next generation sequencing for HLA‐A, B, C, DRB1, DRB3/B4/B5, DQA1, DQB1, DPA1, and DPB1 typing: Toward single‐pass high‐resolution HLA typing in support of solid organ and hematopoietic cell transpl
Smith, Anajane G. , Pereira, Shalini , Jaramillo, Andrés , Stoll, Scott T., Khan, Faisal , Berka, Noureddine , Usenko, Crystal Y., Bettinotti, Maria , Pyo, Chul‐Woo, Nelson, Wyatt C., Askar, Medhat , Geraghty, Daniel E. , Jaramillo, Andres , Stoll, Scott T., Mostafa, Ahmed , Pando, Marcelo Jorge , Willis, Amanda

Mayo Clinic

HLA | June 25, 2019 | Volume: 94 | Issue: 3 | Pages: 296-306

10.1111/tan.13619 | PMID 31237117 Get It

Many clinical laboratories supporting solid organ transplant programs use multiple HLA genotyping technologies, depending on individual laboratory needs. Sequence‐specific primers and quantitative polymerase chain reaction (qPCR) serve the rapid turnaround necessary for deceased donor workup, while sequence‐specific oligonucleotide probe (SSOP) technology is widely employed for higher volumes. When clinical need mandates high‐resolution data, Sanger sequencing‐based typing (SBT) has been the “gold standard.” However, all those methods commonly yield ambiguous typing results that utilize valuable laboratory resources when resolution is required. In solid organ transplantation, high‐resolution typing may provide critical information for highly sensitized patients with donor‐specific anti‐HLA antibodies (DSA), particularly when DSA involve HLA alleles not discriminated by SSOP typing. Arguments against routine use of SBT include assay complexity, long turnaround times (TAT), and increased costs. Here, we compare a next generation sequencing (NGS) technology with SSOP for accuracy, effort, turnaround time, and level of resolution for genotyping of 11 HLA loci among 289 specimens from five clinical laboratories. Results were concordant except for SSOP misassignments in eight specimens and 21 novel sequences uniquely identified by NGS. With few exceptions, SSOP generated ambiguous results while NGS provided unambiguous three‐field allele assignments. For complete HLA genotyping of up to 24 samples by either SSOP or NGS, bench work was completed on day 1 and typing results were available on day 2. This study provides compelling evidence that, although not viable for STAT typing of deceased donors, a single‐pass NGS HLA typing method has direct application for solid organ transplantation.
Distribution of Sonographically Guided Injections of the Subgluteus Minimus and Medius Bursae in Cadaveric Model
Moore, Brittany J. , Johnson, Wade O. , Smith, Jay , Sellon, Jacob L. , Finnoff, Jonathan T.

Mayo Clinic

Medicine & Science in Sports & Exercise | June 25, 2019 | Volume: 51 | Issue: 6S | Pages: 592-592

10.1249/01.mss.0000562280.50168.94 Get It

Characteristics and Scope of Training of Clinicians Participating in the US Direct-to-Consumer Marketplace for Unproven Stem Cell Interventions
Fu, Wayne , Smith, Cambray , Turner, Leigh , Fojtik, Joseph, Pacyna, Joel E. , Fojtik, Joseph Edward , Master, Zubin

Mayo Clinic

JAMA | June 25, 2019 | Volume: 321 | Issue: 24 | Pages: 2463

10.1001/jama.2019.5837 | PMID 31237628 Get It

Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial
Silberstein, Stephen D., Goadsby, Peter J. , Biondi, David M., Hirman, Joe, Cady, Roger , Smith, Jeff , Goadsby, Peter J , Dodick, David W. , Lipton, Richard B.

Mayo Clinic

Cephalalgia | June 25, 2019 | Volume: 39 | Issue: 9 | Pages: 1075-1085

10.1177/0333102419858355 | PMID 31234642 Get It

Background Calcitonin gene-related peptide plays an important role in migraine pathophysiology. We evaluated eptinezumab, an intravenous (IV) anti-calcitonin gene-related peptide monoclonal antibody, for the prevention of chronic migraine. Objective To determine the safety, tolerability, and effectiveness of four dose levels of eptinezumab and to inform the phase 3 development program. Methods This was a phase 2b, parallel-group, double-blind, randomized, placebo-controlled, dose-ranging clinical trial. Men and women (N = 616) aged 18–55 years were included if they had a diagnosis of chronic migraine, with onset at age ≤35 years and history of chronic migraine ≥1 year. During the 28-day screening period, patients must have had ≥15 headache days, including ≥8 migraine days, with ≥5 migraine attacks as recorded in the electronic diary. Patients were assigned in a 1:1:1:1:1 ratio to eptinezumab 300, 100, 30, 10 mg or placebo, administered as a single IV infusion. The primary endpoint was the percentage of patients with a ≥75% decrease in monthly migraine days over weeks 1–12 compared with the 28-day screening period. Results The ≥75% migraine responder rates over weeks 1–12 for eptinezumab 300, 100, 30, and 10 mg were 33.3%, 31.4%, 28.2%, and 26.8%, respectively, versus 20.7% for placebo ( p = 0.033, 0.072, 0.201, 0.294 vs. placebo). Secondary efficacy endpoints (e.g. ≥50% responder rate, change from baseline in frequency of migraine/headache days, and percentage of severe migraines) had results favoring the three higher eptinezumab doses versus placebo. Eptinezumab was well tolerated and adverse event rates were similar to placebo. Conclusions The results of this trial demonstrate that eptinezumab appears effective and well-tolerated for the preventive treatment of chronic migraine and justifies the conduct of pivotal phase 3 trials for migraine prevention. Trial Registration ClinicalTrials.gov identifier: NCT02275117.